Herantis Pharma has announced the appointment Dr Juha Savola, MD, PhD as chief medical officer (CMO). Juha brings over 25 years of global drug development, regulatory and executive leadership experience spanning neurology, gene therapy and rare diseases. Throughout his career, he has helped shape development strategies for innovative therapies from early clinical development through to regulatory approval and commercialisation, with extensive expertise in clinical and regulatory strategy, health authority engagement, programme acceleration and strategic partnering. The appointment of Juha as CMO is intended to support the development of HER-096, as the company evaluates strategic partnering opportunities and works to bring this potential disease-modifier to Parkinson’s disease patients.
Industrials | Comment
Industrials | Comment
Industrials | Comment
Consumer | Comment